

LIMITED REVIEW REPORT

To
The Board of Directors,
M/s Pharmaids Pharmaceuticals Limited,
Hyderabad.


We have reviewed the accompanying statement of unaudited financial results of **PHARMAIDS PHARMACEUTICALS LIMITED** for the Quarter Ended 30th June, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and subject to the non presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & CO
Chartered Accountants
FRN No. 009655S


(GIRDHARI LAL SHINHA)
Partner
M. No. 205140



Place: Hyderabad

Date:
Batgach
& Affiliates
A Network Approved by ICAI

Associate Offices at:

• AHMEDABAD • ASSAM • BANGALORE • CHENNAI • DELHI
• GUWAHATI • JAIPUR • KOLKATA • MUMBAI • TRIVANDRUM



Pharmaids Pharmaceuticals Limited

Statement of Profit and Loss for the Quarter ended 30th June 2019				
Particulars	QUARTER ENDED			YEAR ENDED
	June 2019	March 2019	June 2018	March 2019
	Unaudited	Audited	Unaudited	Audited
Income				
Revenue from Operations	0.00	0.00	0.00	48.10
Other Income	0.00	0.24	0.01	0.52
Total Income	0.00	0.24	0.01	48.62
Expenses				
Cost of Material Consumed	0.00	0.00	0.00	0.00
Purchase of Stock in Trade	0.00	0.00	0.00	35.62
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	0.00	0.00	0.00	0.00
Employee benefit expenses	0.96	0.92	0.86	2.83
Finance Cost	0.08	0.02	0.00	0.05
Depreciation and amortisation expense	0.04	0.07	0.02	0.14
Other expenses	5.78	4.86	2.72	24.75
Total expenses	6.87	5.87	3.60	63.39
Profit/ (loss) before exceptional items and tax	(6.87)	(5.63)	(3.59)	(14.77)
Exceptional items	0.00	0.00	0.00	0.00
Profit/ (loss) before tax	(6.87)	(5.63)	(3.59)	(14.77)
Tax expenses	0.00	0.00	0.00	0.00
Profit/ (loss) for the period from continuing operations	0.00	0.00	0.00	0.00
Profit/ (loss) from discontinued operations	0.00	0.00	0.00	0.00
Tax expense of discontinued operations	0.00	0.00	0.00	(3.70)
Profit/ (loss) from discounting operations (after tax)	0.00	0.00	0.00	0.00
Profit/ (loss) for the period	(6.87)	(5.63)	(3.59)	(18.47)
Other comprehensive income	0.00	0.00	0.00	0.00
Total comprehensive income for the period	0.00	0.00	0.00	0.00
(Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00
Earnings per equity share (for continuing operations)				
a) Basic	(0.20)	(0.17)	(0.11)	(0.54)
b) Diluted	(0.20)	(0.17)	(0.11)	(0.54)
Earnings per equity share (for discontinued operations)				
a) Basic	0.00	0.00	0.00	0.00
b) Diluted	0.00	0.00	0.00	0.00
Earnings per equity share (for discontinued & continuing operations)				
a) Basic	(0.20)	(0.17)	(0.11)	(0.54)
b) Diluted	(0.20)	(0.17)	(0.11)	(0.54)

NOTES: 1. These results were approved at the meeting of the Board of Directors held on August 13,2019. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the current period.

Place : Hyderabad
Date : 13/08/2019

For Pharmaids Pharmaceuticals Limited


Ghisatal Jain
Managing Director
(DIN.No:00404983)

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095. TELANGANA (INDIA)
Ph : 6559 9809, Tele Fax : 040-2756 2126. email : mailpharmaids@yahoo.co.in, Website : www.pharmaids.com

Unit : Survey No. 533, (V) Kondamadugu, (M) Bibi Nagar, District Nalgonda (Telangana). Phone : +91-92470 58492